Breast Cancer Research Foundation

Key takeaways Katie Thurston opened up about being diagnosed with stage 4 breast cancer. She shared the most surprising aspect of her diagnosis at the Breast Cancer Research Foundation’s Hot Pink Party. “I think a lot of us are feeling lumps but thinking, ‘It’s [breast changes due to] our period.’ Well, sometimes it’s not. Sometimes it’s cancer.”

Former

The exciting trial was discussed at ASCO’s annual meeting. Key Takeaways Some people with high-risk breast cancer may be able to safely forgo chemotherapy thanks to a genomic test developed based on BCRF work, according to a new study. The study, known as the OPTIMA trial, showed adding chemotherapy to endocrine therapy provided no added benefit to some patients with ...

The drug was approved for people who are not eligible for immunotherapy. Key Takeaways Datroway (Dato-DXd, or datopotamab deruxtecan) is the first TROP-2 directed antibody-drug conjugate FDA approved for women with metastatic or unresectable triple-negative breast cancer. Specifically, patients who are ineligible for immunotherapy may be candidates for Datroway, givin...

But, there is some good news. Key Takeaways A new study found that stage 4 breast cancer is on the rise in the United States. But, thanks to improvements in treatment, survival rates are also increasing. Breast Cancer Research Foundation investigator Dr. Jose Pablo Leone explains what you need to know about the latest research.

A recent study found th...

The drug was greenlit for certain people with HER2-positive early-stage breast cancer, a monumental change for early-stage breast cancer Key Takeaways Enhertu (trastuzumab deruxtecan, or T-DXxd), a groundbreaking drug for metastatic breast cancer, was recently approved for some people earlier in treatment. Patients may be able to receive the drug before the cancer bec...